Drug
Igsc 20 Infusion
Igsc 20 Infusion: highest development phase Phase 3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| IGSC 20% infusion NCT04842643 | Phase 3 | Primary Immunodeficiency Disease |
Latest
No recent events.
Follow Igsc 20 Infusion on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.